A Study of Lithium and Enlicitide in Healthy Adult Participants (MK-0616-034)

Completed · Phase 1

Conditions studied: Healthy

In brief

Researchers have designed a new study medicine called enlicitide decanoate (MK-0616) as a new way to lower the amount of low-density lipoprotein cholesterol (LDL-C) in a person's blood. Enlicitide decanoate will be called "enlicitide" from this point forward. Lithium (also called lithium carbonate) is a medicine used in bipolar disorder. Researchers want to learn about lithium when taken at the same time with enlicitide. They want to: * Measure a person's blood to find out if the amount of lithium in the blood is the same when lithium is taken alone or with enlicitide * Learn about the safety of lithium when taken alone or with enlicitide and if people tolerate it

Key facts

Study ID

NCT06719544

Run by

Merck Sharp & Dohme LLC

People needed

16

Starts

2025-01-02

Expected to finish

2025-02-06

Last updated by the study team

2025-02-17

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• The key inclusion criteria include but are not limited to the following:
• Is medically healthy with no clinically significant medical history
• Is a continuous non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior to the first dosing

You may not qualify if…

• The key exclusion criteria include but are not limited to the following:
• Has a history or presence of clinically significant medical or psychiatric condition or disease
• Has a history of cancer

Where it is running

• Celerion ( Site 0002) — Tempe, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.